๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Cetuximab plus FOLFIRI as a first-line therapy in metastatic colorectal cancer

โœ Scribed by Daniel G. Haller

Book ID
119219318
Publisher
Frontline Medical Communications, Inc.
Year
2012
Tongue
English
Weight
100 KB
Volume
9
Category
Article
ISSN
1548-5315

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

FOLFIRI plus cetuximab versus FOLFIRI pl
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
โœ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa ๐Ÿ“‚ Article ๐Ÿ“… 2014 ๐Ÿ› Lancet Publishing Group ๐ŸŒ English โš– 289 KB

## Background: Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered with first-line fluorouracil, folinic acid, and irinotecan (folfiri) is unknow